Details of the Drug

General Information of Drug (ID: DMIOUEY)

• Drug Name: AMG 337

Indication

Disease Entry	ICD 11	Status	REF
Clear cell sarcoma	2A60-2C35	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 463.5
  Logarithm of the Partition Coefficient (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 8
• Chemical Identifiers:
  Formula: C23H22FN7O3
  IUPAC Name: 6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one
  Canonical SMILES: C[C@H](C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC
  InChI: InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
  InChIKey: DWHXUGDWKAIASB-CQSZACIVSA-N
• Cross-matching ID:
  PubChem CID: 44181686
  CAS Number: 1173699-31-4
  TTD ID: D0G0BL
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: Clear cell sarcoma
• ICD Disease Classification: 2A60-2C35

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proto-oncogene c-Met (MET)	DTT	MET	1.08E-03	-0.24	-0.4

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health.
• [3] J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).